bcr has signed (11/26/97) with a belgian cy a non exclusive agreement to market cancer implant in US. product price is lower then thrx one. crb dus will become in a few month from now, the only rival of thrx on this specifical market.
For more info on this approach to cancer therapy, see recent announcements from Imagyn (nasd: imti). There is nothing new here. Device companies that think they understand cancer therapy are kidding themselves. While there is still a bit of room for innovation in radiation and chemo, the real play for the future is in immune biotherapeutics... therapeutic vaccines, passive immunotherapy and related technology.
For patch-work device companies to think they can have a real play in the field is a reflection of the probability that management doesn't know what to do next to grow the business... this is amatuer hour.